| Literature DB >> 34059544 |
Omar Fueyo-Rodriguez1, Benjamin Valente-Acosta2, Rodolfo Jimenez-Soto1, Yvette Neme-Yunes1, Sergio Ignacio Inclán-Alarcón1, Roxana Trejo-Gonzalez1, Miguel Ángel García-Salcido3.
Abstract
Immune thrombocytopenia (ITP) has been widely reported as a complication of SARS-CoV-2 infection, but to our knowledge, there have been no reports on the association of the COVID-19 vaccine with thrombocytopenia. Here, we report a case of secondary ITP in a patient who was recently immunised with the messenger RNA COVID-19 vaccine BNT162b2 (Pfizer-BioNTech). © BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: COVID-19; immunological products and vaccines
Year: 2021 PMID: 34059544 DOI: 10.1136/bcr-2021-242220
Source DB: PubMed Journal: BMJ Case Rep ISSN: 1757-790X